CombiGene AB publishes Annual Report for 2018
The auditor’s review report states the following:
Regarding auditors remark of the Annual Report 2018
In September 2018 a unit issue was carried out. Since issue approval by the board did not include warrants, but only shares, the unit issue was introduced on incorrect assumptions and hence was in violation of Section 42, Chapter 8 of the Swedish Companies Act. When the error was noted, the board acted immediately, calling an extraordinary meeting of shareholders in October 2018, which approved the issue of warrants. The company incurred no financial loss, as the cost was borne by an advisor to the company.